Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer
- Monday, December 13, 2021, 7:14
- Business
- Add a comment
NEW YORK, Dec. 13, 2021 /PRNewswire/ — Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has…
About the Author
adminasapcorp has written 42024 stories on this site.